ANGLE (AGL) Competitors

GBX 15.40
-0.10 (-0.65%)
(As of 03:32 AM ET)

AGL vs. VRCI, GENI, ABDX, PRM, LLAI, DXRX, IUG, RENX, NCYT, and AREC

Should you be buying ANGLE stock or one of its competitors? The main competitors of ANGLE include Verici Dx (VRCI), GENinCode (GENI), Abingdon Health (ABDX), Proteome Sciences (PRM), LungLife AI (LLAI), Diaceutics (DXRX), Intelligent Ultrasound Group (IUG), Renalytix (RENX), Novacyt (NCYT), and Arecor Therapeutics (AREC). These companies are all part of the "medical" sector.

ANGLE vs.

Verici Dx (LON:VRCI) and ANGLE (LON:AGL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, community ranking, risk, media sentiment, profitability, valuation and institutional ownership.

Verici Dx's return on equity of -69.68% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
Verici DxN/A -92.28% -47.86%
ANGLE N/A -69.68%-38.07%

ANGLE received 181 more outperform votes than Verici Dx when rated by MarketBeat users.

CompanyUnderperformOutperform
Verici DxN/AN/A
ANGLEOutperform Votes
181
62.20%
Underperform Votes
110
37.80%

Verici Dx has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, ANGLE has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500.

In the previous week, Verici Dx and Verici Dx both had 1 articles in the media. Verici Dx's average media sentiment score of 0.00 beat ANGLE's score of -1.27 indicating that ANGLE is being referred to more favorably in the news media.

Company Overall Sentiment
Verici Dx Negative
ANGLE Neutral

ANGLE has a consensus price target of GBX 70, indicating a potential upside of 351.61%. Given Verici Dx's higher probable upside, analysts plainly believe ANGLE is more favorable than Verici Dx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Verici Dx
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
ANGLE
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Verici Dx has higher earnings, but lower revenue than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verici DxN/AN/A-£11.21M-£0.05-160.00
ANGLE£1.82M22.05-£22.28M-£0.09-171.11

47.3% of Verici Dx shares are held by institutional investors. Comparatively, 27.5% of ANGLE shares are held by institutional investors. 17.0% of Verici Dx shares are held by company insiders. Comparatively, 10.7% of ANGLE shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

ANGLE beats Verici Dx on 7 of the 13 factors compared between the two stocks.

AGL vs. The Competition

MetricANGLEDiagnostics & Research IndustryMedical SectorLON Exchange
Market Cap£40.13M£129.30M£4.87B£1.39B
Dividend Yield1.12%5.44%2.97%11.99%
P/E Ratio-171.11576.48271.571,728.09
Price / Sales22.051,903.652,374.50323,631.13
Price / Cash5.8012.4546.0632.82
Price / Book1.282.954.652.52
Net Income-£22.28M£11.82M£103.06M£179.71M
7 Day Performance31.06%1.59%0.30%1.03%
1 Month Performance20.63%0.89%-5.21%9.03%
1 Year Performance-44.40%-10.32%9.11%16.55%

ANGLE Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRCI
Verici Dx
0 of 5 stars
GBX 8
flat
N/A-42.6%£19.40MN/A-160.0014
GENI
GENinCode
0 of 5 stars
GBX 8.75
-1.4%
N/A-53.6%£15.48M£1.72M-145.8334Gap Down
ABDX
Abingdon Health
0 of 5 stars
GBX 10.50
+2.4%
N/A+39.8%£12.78M£5.34M-1,050.0084
PRM
Proteome Sciences
0 of 5 stars
GBX 3.30
+6.1%
N/A-26.3%£9.74M£7.75M418.0029Gap Up
LLAI
LungLife AI
0 of 5 stars
GBX 31
-1.6%
N/A-39.2%£9.51M£98,566.00-172.2215
DXRX
Diaceutics
1.437 of 5 stars
GBX 104
+1.0%
GBX 150
+44.2%
-0.2%£88.07M£21.90M10,500.00151News Coverage
IUG
Intelligent Ultrasound Group
0 of 5 stars
GBX 9.25
-2.6%
N/A-25.2%£30.24M£10.26M-925.0065Gap Up
RENX
Renalytix
0 of 5 stars
GBX 31
-4.6%
N/A-71.4%£37.18M£2.41M-86.11102Gap Down
NCYT
Novacyt
0 of 5 stars
GBX 55
-1.8%
N/A+42.2%£38.85M£7.87M-152.78120Gap Up
High Trading Volume
AREC
Arecor Therapeutics
0 of 5 stars
GBX 130
-1.9%
N/A-49.4%£39.82M£3.38M-419.3551

Related Companies and Tools

This page (LON:AGL) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners